No Data
BRII-B: 2024 Interim Report
Tengsheng Bo Medicine-B (02137) issued a total of 0.1955 million shares under the stock incentive plan on August 27th.
Tengsheng Boyao-B (02137) issued an announcement on August 16, 2024, based on the audited financial statements for the fiscal year ended June 2021...
Brii Biosciences Records Wider Loss in H1 on Nil Revenue
Tengshengbo Medicine-B (02137.HK) expanded its mid-year loss to 0.283 billion yuan.
On August 19, Guolonghui reported that Tengshengbo Medicine-B (02137.HK) announced that for the six months ended June 30, 2024, the company's other income was 709 million yuan, a decrease of 150 million yuan or 17.5% compared with 859 million yuan for the six months ended June 30, 2023. This was mainly due to the reduction of income recognized on government subsidies. For the six months ended June 30, 2024, R&D expenses were 1,262 million yuan, compared with 2,022 million yuan for the six months ended June 30, 2023.
BRII-B: INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2024
Hang Seng Index: Benefiting from policy support, biotechnology stocks have seen three consecutive months of inflows.
The Hang Seng Index company stated that there are signs of improvement in the recent situation of biotechnology stocks, as well as benefitting from policy support and three consecutive months of inflow of funds.
No Data
No Data
